Wayne Koberstein

  1. A Quick Transition To Late-Stage Clinical Trials 6/1/2023

    “Moving into Phase 3 not only expands the resources you need internally, but some things require a much larger amount of capital, and often a public listing so you can raise larger amounts of money,” says Eric Dobmeier, president and CEO, Chinook Therapeutics.

  2. Companies To Watch: Orca Bio 6/1/2023

    Orca Bio is creating a new cell therapy aimed at bringing rebirth to stem-cell transplantation.

  3. Companies To Watch: Sonoma Biotherapeutics 5/1/2023

    Sonoma Biotherapeutics is bioengineering T cells to create potential cures for autoimmune and inflammatory conditions.

  4. Building It All In-House 5/1/2023

    Kriya’s firm commitment to build or bring all key functions in house may be unusual for such a young enterprise, but it has been consistent from the beginning.

  5. Vor Bio’s Transition Into Clinical Trials 4/3/2023

    Vor Bio’s story, for all of its uniqueness, can teach important lessons in many different quarters, involving everything from mundane tactics to dramatic strategies.

  6. Companies To Watch: KaliVir Immunotherapeutics 4/3/2023

    KaliVir Immunotherapeutics is engineering oncolytic viruses with novel transgenes, and joining them to other immunotherapies, to defeat cancer and cancer relapse.

  7. Companies To Watch: Hummingbird Bioscience 3/1/2023

    Hummingbird Bioscience is joining the forces of computational and systems biology to fight cancer and autoimmune disease.

  8. The Neo CEO 3/1/2023

    Lex Rovner founded her company with support from academic scientists and has headed it since it opened for business in 2018. At that time, she had no prior experience as a company founder or as a CEO.

  9. Scientist-Founders Reshape The Bio Biz 2/1/2023

    Recently, it seems, new scientist-leaders have emerged whose backgrounds and acquired knowledge begin in science but grow to encompass business as well. Mammoth Biosciences is building, and betting, on such a model.

  10. Companies To Watch: Corner Therapeutics 2/1/2023

    Corner Therapeutics is focused on discovering new small molecules that could mimic the body’s natural immune response to generate the robust T-cell response.